The discovery of new protein helps the treatment and prevention of pancreatic cancer

Share This Post

New research has found that pancreatic cancer cells rely heavily on a protein to grow and spread. The research results can bring new treatment and prevention strategies for pancreatic cancer.

The American Cancer Society estimates that up to 61% of patients with early-stage pancreatic cancer can survive for at least 5 years after diagnosis. But some pancreatic cancer subtypes are more aggressive. For example, when diagnosed with pancreatic ductal adenocarcinoma, it is usually already in an advanced stage and its 5-year survival rate is less than 10%. However, new research has identified the main weakness of this aggressive cancer, namely that pancreatic cancer cells are addicted to a key protein. In this new study, Dr. Christopher Vakoc, a professor at the Cold Spring Harbor Laboratory in New York, and his team discovered a gene that encodes a protein that is particularly highly aggressive in pancreatic cancer. It is a postdoctoral fellow in Professor Vakoc ‘s laboratory. Researcher Timothy Somerville is the lead author, and the paper was recently published in the journal Cell Report.

Somerville explained that people diagnosed with pancreatic cancer can live an average of 2 years. However, those with pancreatic ductal adenocarcinoma have unsatisfactory survival. Researchers from Professor Vakoc’s team hypothesized that a specific protein might cause this cancer to be so aggressive. The researchers further studied the protein TP63 using cultures derived from normal pancreatic tissue or pancreatic ductal adenocarcinoma. The analysis showed that the presence of TP63 in the tumor allowed the cancer cells to grow, multiply and metastasize to other parts of the body. .

Somerville explained that one of the encouraging findings is that cancer cells rely on P63 to continue to grow. Therefore, we are investigating the inhibition of P63 activity as a treatment method for patients. “Therefore, understanding why the P63 gene becomes active in some individuals will produce valuable preventive measures that may be very beneficial for the survival of fragile pancreatic cancer populations.”

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy